Adalimumab

Grey

Brand Name(s):Humira , Neotigason
AMGEVITA
Hyrimoz
Imraldi
Hulio

Indication:Refractory chronic non-bacterial osteomyelitis/ osteitis

Rationale:1

Considered:Apr-21

Review Date:Apr-26

Comments:
Adalimumab is not recommended to be available as a treatment option through routine commissioning for refractory chronic non-bacterial osteomyelitis/ osteitis (all ages) due to weak evidence base.